BioSpace News Archive

ICON plc, (NASDAQ: ICLR) today announces that it has been selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial.

Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced an oral presentation at the Exosome Based Therapeutic Development Summit, being held in Boston, MA from October 4-6, 2022.

Cyclerion Therapeutics, Inc. announced its mitochondrial disease-focused corporate strategic plan.

Tempest Therapeutics, Inc. announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company’s TREX1 pipeline asset and will serve as chairperson for the “New Approaches to Solid Tumor Targeting” session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA.

Panbela Therapeutics, Inc. announced that management will participate in the inaugural Roth Healthcare Opportunities Conference on October 6, 2022, in New York, NY.

Bayer, one of the country’s leading life-sciences companies, announced that William Dodero, its current Vice President and Global Head of Litigation, will become the company’s new U.S. General Counsel and Senior Vice President, as well as a member of the U.S. Country Leadership Team.

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced that the Company will present on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the 27th International Hybrid Annual Congress of the World Muscle Society (WMS).

Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada.

Surgalign Holdings, Inc. announced that it has granted restricted stock unit awards to two employees, none of whom was an executive officer, as an inducement for them to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 10,081 shares of Surgalign common stock.